Edition:
United States

miRagen Therapeutics Inc (MGEN.OQ)

MGEN.OQ on NASDAQ Stock Exchange Capital Market

7.34USD
13 Jul 2018
Change (% chg)

-- (--)
Prev Close
$7.34
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
66,297
52-wk High
$15.79
52-wk Low
$5.01

Chart for

About

Miragen Therapeutics, Inc., formerly Signal Genetics, Inc., is a clinical-stage biopharmaceutical company. The Company is engaged in discovering and developing ribonucleic acid (RNA)-targeted therapeutics with a specific focus on microRNAs and their role in diseases where there is a high unmet medical need. Its clinical product... (more)

Overall

Beta: 1.41
Market Cap(Mil.): $221.61
Shares Outstanding(Mil.): 30.19
Dividend: --
Yield (%): --

Financials

  MGEN.OQ Industry Sector
P/E (TTM): -- 214.97 33.20
EPS (TTM): -1.07 -- --
ROI: -36.28 -3.79 13.23
ROE: -40.09 -5.32 15.28

BRIEF-Miragen Therapeutics Reports Q1 Loss Per Share $0.18

* MIRAGEN THERAPEUTICS REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

May 09 2018

BRIEF-Miragen Announces Interim Data From Phase 1 Trial Of Cobomarsen In Mycosis Fungoides

* MIRAGEN THERAPEUTICS ANNOUNCES NEW INTERIM DATA FROM PHASE 1 CLINICAL TRIAL OF COBOMARSEN IN MYCOSIS FUNGOIDES

May 08 2018

BRIEF-Miragen Therapeutics Announces New Data Showing Administration Of MRG-110 Improved Tissue Perfusion And Wound Healing

* MIRAGEN THERAPEUTICS ANNOUNCES NEW DATA SHOWING ADMINISTRATION OF MRG-110 IMPROVED TISSUE PERFUSION AND WOUND HEALING IN LATE STAGE PRECLINICAL STUDIES

Apr 27 2018

BRIEF-Miragen Therapeutics Reports Qtrly ‍loss Per Share $0.29​

* MIRAGEN THERAPEUTICS REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

Mar 14 2018

BRIEF-Miragen Therapeutics Prices Public Offering Of Common Stock

* MIRAGEN THERAPEUTICS, INC. PRICES PUBLIC OFFERING OF COMMON STOCK

Feb 08 2018

BRIEF-miRagen Therapeutics Announces Proposed Public Offering Of Common Stock

* MIRAGEN THERAPEUTICS ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK

Feb 05 2018

Earnings vs. Estimates